Fax: (011) 81-43-256-6506
Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer
Article first published online: 28 JUN 2012
Copyright © 2012 American Cancer Society
Volume 119, Issue 1, pages 45–51, 1 January 2013
How to Cite
Shinoto, M., Yamada, S., Yasuda, S., Imada, H., Shioyama, Y., Honda, H., Kamada, T., Tsujii, H., Saisho, H. and Working Group for Pancreas Cancer (2013), Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer. Cancer, 119: 45–51. doi: 10.1002/cncr.27723
- Issue published online: 17 DEC 2012
- Article first published online: 28 JUN 2012
- Manuscript Accepted: 31 MAY 2012
- Manuscript Revised: 23 MAY 2012
- Manuscript Received: 20 MAR 2012
- short course;
- carbon-ion radiotherapy;
- pancreatic cancer;
- phase 1
The authors evaluated the tolerance and efficacy of carbon-ion radiotherapy (CIRT) as a short-course, preoperative treatment and determined the recommended dose needed to reduce the risk of postoperative local recurrence without excess injury to normal tissue.
Patients radiographically defined with potentially resectable pancreatic cancer were eligible. A preoperative, short-course, dose-escalation study was performed with fixed 8 fractions in 2 weeks. The dose of irradiation was increased by 5% increments from 30 grays equivalents (GyE) to 36.8 GyE. Surgery was to be performed 2 to 4 weeks after the completion of CIRT.
The study enrolled 26 patients. At the time of restaging after CIRT, disease progression with distant metastasis or refusal ruled out 5 patients from surgery. Twenty-one of 26 patients (81%) patients underwent surgery. The pattern of initial disease progression was distant metastasis in 17 patients (65%) and regional recurrence in 2 patients (8%). No patients experienced local recurrence. The 5-year survival rates for all 26 patients and for those who underwent surgery were 42% and 52%, respectively.
Preoperative, short-course CIRT followed by surgery is feasible and tolerable without unacceptable morbidity. Cancer 2013. © 2012 American Cancer Society.